Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
[copy and paste from iHub at the stated time and date by Squid]
Squidster
Re: BOLD4GOLD post# 36303
Sunday, March 19, 2017 9:39:44 AM
Post# 36318
of 73675
Go
Mr. Hartman, I am heavily invested in your company and control more shares than any other individual on HUB. I want to commend you for keeping us informed of how your company and our investment is progressing. Looking forward to future updates.
Hartman has yet to realize, after years of the same move, that no news is better than this sort of press release. We were trending up on the hope of good news coming soon. This sort of PR takes the wind out of the sails essentially saying we don’t have enough good information to anticipate releasing so we’ll try to buoy the price with something that we have on hand. Guarantee this is just a copy and paste of the one-sheeter they pass out to potential investors. Still long and strong HALB but Hartman can sure disappoint in the most naive ways.
I wonder what the timeline is for verifying results on something like this? I know they said it should be a quick study but not sure what qualifies as fast in this industry. I know slow means year(s). I feel like the lack of volume is just everyone holding their collecting breath/wallet waiting to hear something positive or negative. I know I’m just stockpiling some reserve funds to throw in if it comes back positive.
Should be an exciting week…
Great news today! This sounds like a solid study they’ve put together. If this trial achieves what Halberd has been claiming it’s capable of this is going to be HUGE. Too many possible partnerships to name!
On another note, I remember Hartman releasing a PR back in 2022 or something talking about Extendalife where their extracorporeal therapy can target certain antigens tied directly to the aging process. Remember this? I was thinking maybe Hartman himself has been doing trials with this? He has to be closer to 90 if he went to college in ‘59. Maybe he’s a walking PR for their technology!?
I will say I didn’t appreciate Athena GTX’s CEO describing the extracorporeal treatment as a Sci-fi/Star Wars pie-in-the-sky idea during that interview. It’s proven capable of working and is still a large part of why I’m invested here. I wish Hartman would speak to any progress, or to its status in general, while we await news of progress from the nasal spray. A reminder to shareholders and potential investors that all our eggs aren’t in one basket would help rejuvenate some enthusiasm around this company’s potential.
Over a million added in just one trade to finish the day. Someone wanted in badly before this went full rocket ship.
So when these companies go on shark tank and “give away” part of their company this is dilutive financing too. But in reality the partnership often helps both parties by creating better opportunities and thus more value. This is what Hartman is doing. The difference between this and what Hartman did at BIEI is avoiding toxic financing. These people/companies are not going to turn around and sell these shares back at rock bottom prices and haven’t been. It’s why the price has remained relatively stable over the past few years.
Is Hartman ok? Haven’t heard from him directly in some time. He usually loves the pop-in.
Big news next week!
The timing on this is perfection. Between Facebook and ArpaH both intending to advance cures for disease Halberd is in the right place at the right time! Can’t wait for the news to hit about contracts or buyouts from FB and the US Gov’t. Let’s get those financials polished up. This will jump to multiple dollars overnight!
“Discussions have commenced and are in progress with a large medical university to develop potential cures for several neurodegenerative diseases with potential independent validation WITHIN THE YEAR 2022. We plan on sharing the name of this university once an agreement is established.”
Great opportunity for investors bearish on the big boards. HALB is charting it’s own course. Rock solid company, low float, years of experience assembling this puzzle piece by piece (many lessons admittedly learned by Hartman), finally seeing the big picture here. The perseverance of this leadership team is about to pay off for them and all of us!
Firing on all cylinders! T Minus 6…catalysts: Uplisting to OTCQB, additional University partnership, Gov’t contracts for PTSD, JV’s with research organizations, 10th and final Glutamate removal from CSF, NFL CTE relationships too. Good seeing Alec Torelli proactively using his platform to spread the word. Great interview with Dr. Felder here: https://ne-np.facebook.com/alectorelli/videos/i-had-the-pleasure-of-interviewing-dr-felder-inventor-of-the-felder-doctrine-whi/1376056139489970/ It’s taken many years and more than a few bumps along the way but we’re almost there!
This will be bought out within a year if news like this continues. Groundbreaking technology with unprecedented applications. An OTC legend in the making.
So many catalysts converging at the same moment. Can’t wait for the meeting with the Dept of Defense surrounding PTSD treatment as well. When this gets moving it won’t ever look back.
That’s where we differ but to each their own. Some people seem to prefer to ride the popular sentiment train and not ever commit one way or another. Always easy to pile it on Hartman when the volume starts to dip.
You’ve been around long enough to know the news within the last 6months is trending stronger and certainly closer to “results or partnerships” than in any period in the past. You’ve also been around long enough, and I wouldn’t be surprised, to see you post another message stating something along the lines, “Time to buy again?” This is about the 10th time in the last 4 years Hartman’s stock has appeared to go dormant just before another massive run. I once again have my tickets to ride. I encourage anyone to look through the volume of prior run-ups and compare where we are now to where we were then, percentage-wise. We are at the launch site.
Yeah but he was able to do it because of an RS. At that time there also wasn’t the possibility of momentum we have at the moment. That was a faulty combination. Hartman for all his missteps has learned a few things. I think he’s sitting on the best PR’s for after the QB uplisting.
I agree, each of these should have gone on without as much as a note in the Annual
Report. With all the talk a month ago from Hartman around JV’s/buyouts/mergers with potential large pharmaceutical players you wouldn’t have to be a genius to know anything less (much less in this case) wouldn’t be received well by your shareholders. The art of the PR has always failed this leadership team. Glad to see them considering any and all avenues but this isn’t news that needs to be recognized with anything more than a sentence in a required report. Maybe Hartman is afraid of giving up too much or being swindled by big pharma? Possibly why he consistently swims so close to the bottom.
To me this is like the flood in the times of Noah. Easy to criticize as most start-ups are but what they are building is not easily recognized for it’s importance. When the waters start to rise will be fast and the world for those invested will never be the same.
We’re here because of the research and the work Hartman and Felder are doing. Hartman was smart to ditch the hole BIEI was in. He continues to prove he’s devoted to making this work. He’s been preaching the same baseline sermon for as long as I’ve been here. Nice to finally see some positive results as a means to all the ups and downs they’ve faced over the years.
This happens all the time, doesn’t mean the work that Hartman is currently doing is any less valid.
The drone endeavor was not this company. That was HALB before Hartman. Anything from this ticker before 2020 doesn’t apply to it’s current operation. The best place to find the history of Hartman and this company prior to that is with BIEI.
They’ve been working to get this technology recognized for the last 20 years, yes. You’re right. That’s just how long this takes. Hartman has made mistakes along the way (he admits this, toxic financing) but the pins are set for him to finally deliver a strike for himself and this company. Not a scam. Just a start-up biotech working toward the same dream for the last two decades.
From what I’ve noticed this seems to have a better second day after a big PR drop *knock on wood. Probably from all the Sykes followers dumping on news (any news, don’t bother reading the content). This news is big. It’s what we’ve been waiting for.
Moot, that’s right. Thank you. Your points are taken. Good to see evidence Hartman isn’t letting these provisional applications go to waste.
Demonstrating it’s a step in the process to achieving fully recognized patent status. Similar to the School House Rock episode that shows the process of how a Bill becomes a Law. Each step is a precursor to the next until the final Bill becomes Law. You’re point isn’t wrong it’s just mute. It’s like arguing that ground beef isn’t and will never be a burger. It can and it will become a burger if the next steps in the process are enacted upon it. Otherwise you are correct, it remain ground beef, spoils and eventually is thrown out.
It’s a continuation of a provisional patent application filed in 2018 when this was operating under Premier Biomedical. Once again providing evidence these provisional patents or provisional applications, whichever term you prefer, aren’t just Press Release wall art. They have potential to become fully recognized US patents.
https://www.globenewswire.com/en/news-release/2018/02/12/1339167/32339/en/Anti-Aging-Patent-Application-Filed-Exclusive-Commercial-Rights-to-Premier-Biomedical-Inc.html
Hartman didn’t try to push any more fluff news this week. I think that’s a good sign that he has some good stuff to release in the near future.
It’s good to see Dr. Felder wanting to be involved in this critical phase of his extracorporeal treatment development. It shows it’s demonstrating real promise. It also shows maybe some relationships are on the mend between both Hartman and Felder. The more effective these two can communicate and cooperate the better off we’ll all be as investors. Dr. Reyes, enjoy your time and thank you for all you’ve done to help move this forward.
It was definitely tough for us BIEI investors to make sense of that, especially during the transition to HALB. You’re right. A lot of people are still upset about it and unwilling to let him forget. Which I can’t blame them. When Dr. Felder left and went to HALB so did I. I’m following the technology and those patents. I do my best to defend Hartman along the way because I don’t think he’s a crook, he’s just not a great businessman. Hartman, to me, would be a great lead on a R&D team. He likes to develop technologies and the relationships around them. If he brought in someone else to make the public statements and broker the deals HALB would be better off. All that being said, I like his work ethic and I think he only wants for this to be successful. To that end, if he is, then so is my investment.
I cannot answer on his behalf but Hartman is always friendly and usually responds within a few days. If you have questions you’d like to have answered you should reach out to him.
Hartman and his accomplishments at BIEI are the building blocks that made HALB what it is today. Hartman mentions in one of the early PRs he took the best parts of Premier Biomedical and those prior business relationships and used them to form the structure of Halberd Corp. So yes, those do apply. The best part is it won’t be long before Vita Shield Max is available for purchase as well.
You’re incorrect. Painreliefmeds.com
Maybe you weren’t here yet but it hit .109 about a month ago.
???
This is like blaming Nestlé for Ralph Lauren having a bad quarter. Just because they own the company does my mean they’re involved in the day to day operations.
They say the greatest artists know when their work is finished. You can ruin a great piece with “one more” adjustment. Watching Hartman turn down deals seems, to me, to have this same effect. I’m not sure to what point he’s trying to develop some of these technologies? If he doesn’t have the money to go all the way through the clinical trials he needs to understand when it’s time to put down his chisel, grab his pen and sign on the dotted line. Licensing deals, JV’s, this needs momentum from outside the Hartman PR machine.
Again, something Hartman said he was going to do from the beginning. Thank you for verifying Hartman as a man of his word.